The PRECISE-DIET Trial
Precision Nutrition Versus Standard Dietary Care: Effect of Personalised Nutrition Guidance Based on Continuous Glucose Monitoring in Type 2 Diabetes - The PRECISE-DIET Trial
People with type 2 diabetes receive standard dietary advice to improve glycaemic control. However, blood glucose responses to the same foods can vary considerably between individuals. This randomised controlled trial aims to investigate whether personalised carbohydrate recommendations guided by continuous glucose monitoring (CGM) improve glycaemic control (HbA1c) compared with standard dietary care.
A total of 130 adults with type 2 diabetes will be randomly assigned to one of two groups. The study will include a 6-month intervention period followed by a 6-month follow-up period. The intervention group will receive dietitian-led personalised carbohydrate recommendations informed by CGM data, supplemented by group-based education in carbohydrate counting. The control group will receive standard individual dietary counselling provided by a dietitian without the use of CGM.
The primary outcome is the between-group difference in change in HbA1c from baseline to 6 months.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Zandra Overgaard Pedersen, MSc. Health Science
- 電話番号:24456114
- メール:zandra.overgaard.pedersen@regionh.dk
研究連絡先のバックアップ
- 名前:Bettina Ewers, PhD
- 電話番号:30912997
- メール:bettina.ewers@regionh.dk
研究場所
-
-
-
Herlev、デンマーク、2730
- Steno Diabetes Center Copenhagen
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- T2D
- Diabetes duration of ≥12 months
- Age ≥18 years
- HbA1c ≥58 mmol/mol
- Attending the SDCC outpatient clinic
- Provided voluntary signed informed consent
Exclusion Criteria:
- Inability to understand the study information
- Medical complications that prevent lowering HbA1c to below 58 mmol/mol
- Use of insulin therapy
- Low daily carbohydrate intake (defined as below 25 E% or 100 g/day) prior to study inclusion
- Systematic use of corticosteroids
- Using or requiring a specialised diet (e.g., protein restriction in kidney disease)
- Circumstances that affect HbA1c (e.g., liver disease and anaemia)
- Known or suspected drug or alcohol abuse
- Pregnancy or breastfeeding or plans of pregnancy within the study period
- Participation in other clinical trials
- Individuals with a BMI of <27 kg/m²
- Initiation of GLP-1 receptor agonist or SGLT inhibitor therapy within the previous 3 months
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Personalised dietary intervention
CGM-supported personalised carbohydrate recommendations |
Participants will receive structured, personalised dietary recommendations supported by continuous glucose monitoring (CGM). Initial carbohydrate recommendations will be based on approximately 35% of total energy intake and translated into individual targets expressed as grams of carbohydrate per day and per meal. These targets will be adjusted throughout the intervention based on individual needs and glycaemic responses rather than prescribed as fixed amounts. CGM data will be used to assess individual postprandial glucose responses and guide adjustments to carbohydrate intake and its distribution throughout the day. The intervention will also include education in basic carbohydrate counting and dietitian-led counselling to support the implementation and maintenance of dietary changes. |
|
アクティブコンパレータ:Standard dietary counselling
Standard dietary counselling for type 2 diabetes |
Participants will receive standard dietary counselling for type 2 diabetes based on current dietary recommendations, without CGM-guided personalisation of carbohydrate intake. The counselling will include one initial 60-minute individual consultation with a dietitian, followed by two 30-minute follow-up consultations. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in HbA1c
時間枠:Baseline to 6 months
|
Between-group difference in change in HbA1c (mmol/mol) from baseline to 6 months |
Baseline to 6 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in HbA1c at 12 months
時間枠:Baseline to 12 weeks and 12 months
|
Between-group difference in HbA1c change (mmol/mol) |
Baseline to 12 weeks and 12 months
|
|
Time in range (TIR)
時間枠:Baseline, 6 and 12 months
|
Percentage of CGM time with glucose 3.9-10.0 mmol/L |
Baseline, 6 and 12 months
|
|
Time above range (TAR)
時間枠:Baseline, 6 and 12 months
|
Percentage of CGM time with glucose >10.0 mmol/L |
Baseline, 6 and 12 months
|
|
Time below range (TBR)
時間枠:Baseline, 6 and 12 months
|
Percentage of CGM time with glucose <3.9 mmol/L |
Baseline, 6 and 12 months
|
|
Estimated HbA1c
時間枠:Baseline, 6 and 12 months
|
HbA1c estimated from CGM data (mmol/mol) |
Baseline, 6 and 12 months
|
|
Change in glycaemic variability
時間枠:Baseline, 6 and 12 months
|
Coefficient of variation (%) derived from CGM |
Baseline, 6 and 12 months
|
|
Body mass index (BMI)
時間枠:Baseline, 6 and 12 months
|
kg/m² |
Baseline, 6 and 12 months
|
|
Waist and hip circumference
時間枠:Baseline, 6 and 12 months
|
cm |
Baseline, 6 and 12 months
|
|
Blood pressure
時間枠:Baseline, 6 and 12 months
|
Systolic and diastolic (mmHg) |
Baseline, 6 and 12 months
|
|
plasma glucose
時間枠:Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Plasma insulin
時間枠:Baseline, 6 and 12 months
|
pmol/L |
Baseline, 6 and 12 months
|
|
C-peptide
時間枠:Baseline, 6 and 12 months
|
pmol/L |
Baseline, 6 and 12 months
|
|
Total cholesterol
時間枠:Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
LDL cholesterol
時間枠:Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
HDL cholesterol
時間枠:Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Triglycerides
時間枠:Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Diabetes distress (questionnaire)
時間枠:Baseline, 6 and 12 months
|
Problem Areas in Diabetes (PAID) score |
Baseline, 6 and 12 months
|
|
Treatment satisfaction (questionnaire)
時間枠:Baseline, 6 and 12 months
|
Diabetes Treatment Satisfaction Questionnaire (DTSQ) score |
Baseline, 6 and 12 months
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in glucose-lowering medication
時間枠:Baseline, 6 and 12 months
|
Changes in type and dose of glucose-lowering medication |
Baseline, 6 and 12 months
|
|
Personality traits (questionnaire)
時間枠:Baseline
|
Big Five Inventory (BFI-44) scores |
Baseline
|
|
Dietary intake
時間枠:Baseline and 6 months
|
Total energy intake and macronutrient composition from a 3-day food record |
Baseline and 6 months
|
|
Physical activity
時間枠:Baseline and 6 months
|
Physical activity level measured with an AX3 accelerometer worn for 7 days |
Baseline and 6 months
|
|
Carbohydrate estimation ability (questionnaire)
時間枠:Baseline, 6 and 12 months
|
Accuracy of participants' carbohydrate estimates |
Baseline, 6 and 12 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- H-26063596
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。